Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Enterprise Value (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Enterprise Value readings, the most recent being -$185.8 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 118.76% to -$185.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$185.8 million, a 118.76% decrease, with the full-year FY2025 number at -$188.9 million, down 399.1% from a year prior.
  • Enterprise Value hit -$185.8 million in Q4 2025 for Enanta Pharmaceuticals, up from -$188.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$36.4 million in Q2 2024 to a low of -$386.6 million in Q2 2023.
  • Median Enterprise Value over the past 5 years was -$246.6 million (2021), compared with a mean of -$233.4 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 90.59% in 2024 and later tumbled 461.01% in 2025.
  • Enanta Pharmaceuticals' Enterprise Value stood at -$259.1 million in 2021, then increased by 17.21% to -$214.5 million in 2022, then plummeted by 57.2% to -$337.2 million in 2023, then skyrocketed by 74.8% to -$85.0 million in 2024, then tumbled by 118.76% to -$185.8 million in 2025.
  • The last three reported values for Enterprise Value were -$185.8 million (Q4 2025), -$188.9 million (Q3 2025), and -$204.1 million (Q2 2025) per Business Quant data.